BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Covalon To Hold Annual and Special Meeting of Shareholders on Wednesday, March 8, 2023

  Covalon Technologies Ltd. has announced that the annual and special meeting of shareholders of the Company will be held on Wednesday, March 8, 2023 at 3:30pm EST.

  February 28, 2023

   · 

  4 min read
• Biotech Beach

  Ionis to present at upcoming investor conferences - February 28, 2023

  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences.

  February 28, 2023

   · 

  1 min read
• Pharm Country

  U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….

  U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

  February 28, 2023

   · 

  42 min read
• Genetown

  Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease

  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced top-line results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug, in dry eye disease patients.

  February 28, 2023

   · 

  11 min read
• Biotech Beach

  Sonendo Continues to Invest in University Endodontic Programs, Research and Development Initiatives and Professional Education

  Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced its continued investment in endodontics, with a specific focus on clinical training and education.

  February 28, 2023

   · 

  3 min read
• Business

  Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023

  Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update.

  February 28, 2023

   · 

  1 min read
• Business

  ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

  ADC Therapeutics SA today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.

  February 28, 2023

   · 

  24 min read
• Business

  Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  Bicycle Therapeutics plc today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent corporate updates.

  February 28, 2023

   · 

  10 min read
• Pharm Country

  Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference

  Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023.

  February 28, 2023

   · 

  1 min read
• Pharm Country

  Premia Spine’s TOPS™ Facet Joint Replacement Demonstrates Significant Improvement in All Patient-Reported Outcome Measures Versus Fusion in FDA Trial

  Premia Spine today announced publication of two-year outcomes from the TOPS facet joint replacement system’s clinical trial in the Journal of Neurosurgery Spine.

  February 28, 2023

   · 

  4 min read